BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 21, 2003
View Archived Issues
Amgen Hits Endpoints In First Enbrel Psoriasis Phase III Trial
The first of two Enbrel Phase III trials in psoriasis hit its primary and secondary endpoints, pushing Amgen Inc. to the halfway point in its quest to grow the blockbuster drug through the addition of another large market. (BioWorld Today)
Read More
NPS's Phase III Bone Treatment Tested In Shuttle's Microgravity
Read More
FDA's Authority Over Cloning Questioned At Council Meeting
Read More
Holiday Notice
BioWorld's offices were closed Monday in observance of the Martin Luther King Jr. holiday in the U.S. No issue was published that day.
Read More
Amylin Sells 9.2M Shares, Raises $152.7M For Symlin
Read More
Other News To Note
Read More
Appointments And Advancements
Read More